Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Six human ovarian cancer cell lines and samples of ascites cells isolated from 27 patients with stage III or IV ovarian papillary serous cystadenocarcinoma were studied individually to test whether recombinant human Mullerian inhibiting substance (rhMIS) acts via its receptor. To do these experiments, we scaled up production of rhMIS and labeled it successfully with biotin for binding studies, cloned the human MIS type II receptor for mRNA detection, and raised antibodies to an extracellular domain peptide for protein detection. These probes were first tested on the human ovarian cancer cell lines and then applied to primary ovarian ascites cells. rhMIS inhibited colony growth of five of six cell lines that expressed the human MIS type II receptor mRNA by Northern analysis while not inhibiting receptor-negative COS cells. Flow cytometry performed on MIS-sensitive ovarian cancer cell lines demonstrated specific and saturable binding of rhMIS (Kd = 10.2 nM). Ascites cells from 15 of 27 or 56% of patients tested bound biotinylated MIS (MIS-biotin) and, of the 11 that grew in soft agarose, 9 of 11 or 82% showed statistically significant inhibition of colony formation. Of the 15 patients who bound biotinylated MIS, mRNA was available for analysis from 9, and 8 of 9 expressed MIS type II receptor mRNA by reverse transcription-PCR, showing a statistically significant correlation, compared with binding, by chi2 analysis (P = 0.025). Solid ovarian cancers were positive for the MIS type II receptor protein by immunohistochemical staining, which colocalized with staining for antibody to CA-125 (OC-125). Thus, the detection of the MIS type I receptor by flow cytometry may be a useful predictor of therapeutic response to MIS and may be a modality to rapidly choose patients with late-stage ovarian cancer for treatment with MIS.
Masiakos
P T
PT
Pediatric Surgical Research Laboratories, Department of Surgery, The Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
MacLaughlin
D T
DT
Maheswaran
S
S
Teixeira
J
J
Fuller
A F
AF
Shah
P C
PC
Kehas
D J
DJ
Kenneally
M K
MK
Dombkowski
D M
DM
Ha
T U
TU
Preffer
F I
FI
Donahoe
P K
PK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000595:Amino Acid Sequence; D000818:Animals; D054304:Anti-Mullerian Hormone; D001201:Ascites / Q000235:genetics / Q000473:pathology; D019556:COS Cells; D002455:Cell Division / Q000187:drug effects; D003536:Cystadenocarcinoma / Q000235:genetics / Q000473:pathology*; D005260:Female; D005333:Fetus; D006023:Glycoproteins; D006131:Growth Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009095:Mullerian Ducts; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology*; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology; D051381:Rats; D018000:Receptors, Peptide / Q000235:genetics* / Q000378:metabolism*; D018125:Receptors, Transforming Growth Factor beta; D011994:Recombinant Proteins / Q000378:metabolism; D013735:Testicular Hormones / Q000378:metabolism / Q000494:pharmacology*; D013737:Testis / Q000196:embryology / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured
D006023:Glycoproteins; D006131:Growth Inhibitors; D010446:Peptide Fragments; D018000:Receptors, Peptide; D018125:Receptors, Transforming Growth Factor beta; D011994:Recombinant Proteins; D013735:Testicular Hormones; C084621:anti-Mullerian hormone receptor; D054304:Anti-Mullerian Hormone